| Project and Funder/Partner (funder/partner in brackets) |
Duration |
Start & End Date | |
| Clinical Trials | |||
1 | DART – Development of Antiretroviral therapy in Africa (UK Medical Research Council and IDI Co-funding) |
6 Years | May 2003 – Early 2009 |
2 | Second Line Antiretroviral therapy in Africa – DART sub study (UK Medical Research Council) |
2Years |
Mar 2007 – Mar 2009 |
3 | TMC278-C209: A Phase III, randomized, double-blind trial of TMC278 75 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and entricitabine in antiretroviral-naïve HIV-1 infected subjects (Tibotec Pharmaceuticals) |
2 Years |
Mar 2008 – Mar 2010 |
4 | Partners in Prevention Study : Phase III randomized placebo-controlled trial HSV-2 suppression to prevent HIV transmission among HIV discordant couples (Bill and Melinda Gates and University of Washington) |
3 Years |
Mar 2005 – Mar 2008 |
5 | Hepatitis B Virologic Response in HIV Co-infected Patients on Treatment with Tenofovir Versus Lamivudine Containing Regimens: A Randomized Controlled Study ( Gilead and IDI co-funding) |
16 Years |
May 2007 – Sept 2008 |
6 | A Phase I/II Plot Study Assessing the Immunogenicity of 2 Pneumococcal Vaccines in HIV Patients undergoing Delayed Versus Immediate Immunization: Academic Collaboration between the Canadian Trials Network and IDI to pursue HIV/AIDS Clinical Trials (University of British Columbia and Providence Healthcare Society) |
1 Years |
Mar 2008 – Feb 2009 |
7 | Parallel Comparison of Tenofovir and Emtricitabine/tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition within HIV-1Discordant Couples (Bill and Melinda Gates and University of Washington) |
5 Years |
Feb 2008 – Jan 2013 |
8 | Minocycline in the treatment of HIV-associated cognitive impairment in Uganda (Neurologic AIDS Research Consortium) |
2 Years |
Jan 2008 – Dec 2009 |
9 | Anti-retroviral therapy of AIDS-related Kaposi’s Sarcoma in Africa (US national Institutes of Health via University of California San Francisco) |
4 Years |
May 2007 – May 2011 |
| Phase I Pharmacokinetic Studies | |||
10 | Pharmacokinetic interaction between co-artem and either nevirapine, efavirenz or rifampicin in HIV positive Ugandan patients (Health Research Board; Department of Foreign Affairs, Ireland) |
6 months |
Feb 2008 – Jul 2008 |
11 | Comparison of nevirapine levels with and without dose escalation in HIV infected patients commencing antiretroviral therapy who are also receiving rifampicin based anti-tuberculous therapy ( University of Liverpool) |
6 months |
Feb 2008 – Jul 2008 |
12 | Lumefantrine pharmacokinetics when administered as a fixed dose combination with artmether in HIV-positive patients on Kaletra ( University of Liverpool) |
6 Months |
Feb 2008 – July 2008 |
13 | Comparison of the pharmacokinetics of antiretroviral agents in HIV infected Ugandan women during and after pregnancy (Falk Foundation, North Western University, Chicago) |
6 months |
Feb 2008 – Jul 2008 |
14 | Food – antiretroviral interaction study (Health Research Board, Ireland) |
1 Year |
Mar 2008 – Mar 2009 |
15 | Improving chemotherapy of AIDS, tuberculosis, and malaria in adults, pregnant women and children by studying the pharmacology of drugs (NACCAP-INTERACT) |
5 Years |
Feb 2006-Feb 2011 |
| Observational Studies | |||
16 | The Infectious Diseases Institute AIDS Cohort (IDI funded) | On-going | Apr 2004 |
17 | An International multi-centre cross-sectional survey of HIV-1 viral co-receptor tropism by clade and region at select centres of excellence in the developing world (Pfizer) |
1 year | Oct 2007 – Oct 2008 |
18 | Comparison of CD4 monitoring alone versus CD4 plus viral load monitoring for individuals on antiretroviral therapy in Africa (US National Institutes of Health) | 18 months | Oct 2007 – Apr 2009 |
19 | Human Herpesvirus-8 Replication in a Hyper-Endemic Region ( Fred Hutchinson Cancer Research Center Early Detection Initiative, University of Washington) | 3 years | Jul 2007 – Jul 2010 |
20 | HHV-8 (2) Replication and Progression to Malignancy in Africa Study (Doris Duke Charitable Fund via the University of Washington) | 3 years | Dec 2005 – Dec 2008 |
21 | Immune Reconstitution Inflammatory Syndrome in Ugandan HIV-infected patients after initiation of potent anti-retroviral therapy: (US National Institutes of Health via The Academic Health Center at the University of Minnesota and Tibotec Pharmaceuticals) | 40 months | May 2006 – Jun 2008 |
22 | Preparation for conducting phase III Trials of novel TB vaccines in Ugandan infants and adolescents (European and Developing Countries Clinical Trials Partnership co-funded by AERAS TB Vaccine Foundation) | 5 years | 2007 – 2011 |
23 | The Immune Correlates Project (Bill and Melinda Gates Foundation and University of Washington) | 2 years | Oct 2006 – Oct 2008 |
24 | Social and Behavioral Research Capacity Building in Uganda (US National Institutes of Health) | 5 years | Sept 2007 – Jul 2012 |
25 | Adult retention in ART programs (Family Health International) | 18 months | Not yet started |
26 | Adult Adherence to Antiretroviral Therapy in the President’s Emergency Plan for AIDS Relief (Family Health International) | 18 months | Not yet started |
27 | African-Dutch Partnership to Strengthen Research Capacity (co-funded through NACCAP-INTERACT, the European Commission, and the Institute of Tropical Medicine) Project C: Implementation Research: Operational Aspects of Diagnosis and Treatment for HIV Infection and TB at the District Level Project F: The Pathogenesis of TB Immune Reconstitution Inflammatory Syndrome (TB-IRIS), and the Incidence of TB-IRIS and Other Adverse Effects in TB/HIV Co-Infection and HIV Patients Commencing HAART | 3 years | Feb 2007 – Feb 2010 |
28 |
HIV dementia and sensory neuropathy in Uganda (US National Institutes of Health via Johns Hopkins University) | 18 months | Jul 2008 – Dec 2009 |
| Capacity Building Grants | |||
29 |
Academic Alliance Exchange Programme in International Medicine: Sewankambo Clinical Scholars; ID Fellows; MMED students; International Fellows ( Gilead) | On-going | Since Jul 2006 |
30 |
Capacity Building in Clinical Research in Infectious Diseases (Vlaamse Interuniversitaire Raad via the Institute of Tropical Medicine, University of Antwerp) | 5 years | Apr 2007 – Mar 2012 |
31 |
African-Dutch Partnerships to strengthen research capacity (NACCAP-INTERACT and Europe AID) – listed above |
3 years | Feb 2007 – Feb 2010 |
| Other Grants | |||
32 | Global Fund Round 3 studies: |
1 year | Jul 2007-Jun 2008 |
